Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
about
Imaging radiation response in tumor and normal tissue.Use of Quantitative Dynamic Contrast-Enhanced Ultrasound to Assess Response to Antiangiogenic Therapy in Children and Adolescents With Solid Malignancies: A Pilot StudyActivity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial.Translational imaging endpoints to predict treatment response to novel targeted anticancer agents.Role of dynamic contrast-enhanced sonography for characterization and monitoring of extramedullary myeloma: comparison with serologic data.A phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC).Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter studyCritical appraisal of sorafenib in the treatment of Chinese patients with renal cell carcinomaTargeting immune suppressing myeloid-derived suppressor cells in oncology.Targeted therapies in renal cell cancer: recent developments in imagingPhase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.New onset of multiple keratoacanthomas and palmoplantar hyperkeratosis caused by the treatment of metastatic renal cell carcinoma with a new generation multi-kinase inhibitor.Current concepts of metastasis in melanoma.Serum interferon alpha receptor 2 mRNA may predict efficacy of interferon alpha with/without low-dose sorafenib for metastatic clear cell renal cell carcinomaPharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors.A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity.Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan.Targeted agents for the treatment of metastatic melanoma.The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune CellsIdentification and functional characterization of pVHL-dependent cell surface proteins in renal cell carcinoma.Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic ReviewEffects of interferons and double-stranded RNA on human prostate cancer cell apoptosis.Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a Phase III overview.Recent discoveries in the genetics of melanoma and their therapeutic implications.Novel therapeutics for the treatment of metastatic melanoma.Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?Phosphorylated 4E-BP1 is associated with poor survival in melanoma.Dynamic contrast-enhanced ultrasonography (DCE-US): a new tool for the early evaluation of antiangiogenic treatment.Immune-related biomarkers for diagnosis/prognosis and therapy monitoring of cutaneous melanoma.Regional treatment strategies for in-transit melanoma metastasis.Sorafenib for the management of advanced renal cell carcinoma.Systemic therapy for advanced renal cell carcinoma.Evaluation of treatment response in patients with metastatic renal cell carcinoma: role of state-of-the-art cross-sectional imaging.Sorafenib in melanoma.Current status of pharmacotherapy against metastatic renal cell carcinoma in Japan.Recent advances in the treatment of metastatic renal cell carcinoma.Sorafenib and thyroid cancer.Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor ActivityDynamic contrast-enhanced ultrasound for quantification of tissue perfusion.Targeting the tumor stroma in hepatocellular carcinoma.
P2860
Q26798266-1CE2BC2D-DC1F-457B-8B70-E8FF7EBD81BEQ30357444-C70C1A05-CAEE-4A97-9CDE-37EECC52F8A4Q30429122-24FD0CB1-D77A-4AD7-8DFE-1AAF2EAC059CQ30465097-68587551-AD94-48F7-B43D-4155A3D9987EQ30669943-A611E61D-B328-4A0B-9C0B-FDCD84921643Q33393378-9A42B84E-914A-4AE6-B2CC-D54BDB1507D3Q33485003-59B64243-1CF4-44A5-9482-76779961470DQ33754122-58D51015-58F3-43BA-BD4A-A83AA13D8F2DQ34082067-BD93A693-8B27-4EDA-A4C8-6A07C09E0493Q34088696-B87CF3E5-2526-4F87-B7E1-49DAF1D4BA32Q34200743-79100653-0186-424C-A996-A23EC690ABE3Q34524166-0DCFD13F-405E-4733-86CF-E6EA623CCC6FQ34610427-4959BB70-A4C8-439E-A119-DAC34C31BC79Q34995745-B370CE38-60D2-41E7-84D4-F2AC9A02F035Q35069647-D4679146-9429-4822-8D40-09C0C66846C7Q35471445-E2BA424A-81E2-4334-B994-08BEB7A9CB0FQ35801911-D9815F37-6798-4FF7-93FE-25CDE1F66319Q35822194-F0B425AE-9FE3-49BA-A1AC-65343BFD4A19Q35988731-4B3F533A-16BB-4D42-A6A5-0952FD94E6B1Q36088193-236322F8-DC99-4CE7-B03F-6679070D939EQ36270115-6C7EC411-5A61-4BB8-B755-BB9596CEDF44Q36629549-E67CA34E-5CC7-456B-BEA9-767DEFF25DE4Q36950466-5528DC87-ADDB-4A80-B2C0-95E86296CAD6Q37024839-47E8B913-DDE9-49F7-8316-B7ADDC18D917Q37486788-54823AFA-DC3C-4ED8-B769-ECC77A4DFCF3Q37688711-005C39D2-074D-4361-8D67-BB096F7F3FC9Q37716504-C3ECDF6E-6837-4564-B45B-2CFC527BEEE5Q37727867-CB6BFBE4-940A-4F22-B35C-CAD847FAC44BQ37801939-1A8C38E3-601A-4732-AF8E-4DC1F5F4C9A7Q37812815-8FB37AFC-EAE9-427B-A45B-ACA7F41789C5Q37894667-E3BBE75A-19E6-4F3D-B475-FF2398F46C6EQ37905583-9B72D148-0304-4F0E-854D-F0B9A315A24EQ37965053-CE0342DA-4A8D-4B84-ADE0-9C85B2BBAB66Q37990977-17633FC5-8980-4F82-BEC2-946ACE165C67Q37997462-4F976683-E282-49F7-938E-9BEF61D92165Q38108392-6F369CD3-135B-47D1-A07F-5B06AB49ED35Q38118647-8263BDA2-0AF0-4D05-A4E7-C1E6D49C88EAQ38203261-E9F484CD-5BD3-4EEF-9C9E-25898ACBF883Q38329582-87CAB1BF-69C9-4813-AB52-8746FE9AD3F6Q38366586-A3BB193D-1BA9-40C6-A79C-D329173FA374
P2860
Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Phase I trial of sorafenib in ...... rcinoma or malignant melanoma.
@en
type
label
Phase I trial of sorafenib in ...... rcinoma or malignant melanoma.
@en
prefLabel
Phase I trial of sorafenib in ...... rcinoma or malignant melanoma.
@en
P2093
P50
P1476
Phase I trial of sorafenib in ...... rcinoma or malignant melanoma.
@en
P2093
Eric Brendel
Eric Zafarana
Jean Charles Soria
Jean-Pierre Armand
Linda Chami
Nathalie Lassau
Veronique Landreau
P304
P356
10.1158/1078-0432.CCR-06-1432
P407
P577
2007-03-01T00:00:00Z